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Cardiopuhnonary effects of cuprophane—activated plasma in the swine.
Hemodialysis with cuprophane membrane is associated with comple-
ment activation and the formation of anaphylatoxins. Frequently, it is
also complicated by various adverse reactions which include hypoxe-
mia and hemodynamic changes. This study examined the cardiopul-
monary effects of cuprophane membrane on experimental animals. To
support the hypothesis that these effects were mediated by complement
activation products, the effects of zymosan—activated plasma and
CSeArg challenge on the same variables were compared. We showed
that intravenous infusion of autologous cuprophane—activated plasma
into swine produced severe pulmonary hypertension, hypoxemia and
leukopenia. In addition, mean systemic arterial pressure fluctuated and
cardiac output fell. Infusion of zymosan—activated plasma produced
similar results, suggesting that complement activation products are
responsible for these alterations. Similar responses to porcine CSa,JeSArg
infusion suggested further that this polypeptide was the mediator. When
swine were subjected to extracorporeal circulation using cuprophane
membrane but without dialysis, acute pulmonary hypertension was
seen preceding the onset of significant leukopenia. These data suggest
that blood contact with cuprophane membrane produces both pulmo-
nary and systemic hemodynamic changes, which are mediated by
complement activation products. Furthermore, these products andlor
other humoral factors, but not leukoagglutination, cause the pulmonary
hypertension.
Hemodialysis with cuprophane membrane is often accompa-
nied by adverse reactions such as chest pain, dyspnea and,
hypotension [1—3]. Intradialytic hypertension is much less com-
mon, but occasionally occurs [2—5]. An anaphylactoid reaction
is sometimes observed when a new cuprophane membrane is
employed, which has been referred to by some investigators as
the First—use syndrome [4—8]. Activation of the complement
cascade through the alternative pathway also occurs during
cuprophane hemodialysis. Formation of the complement acti-
vation products C3a and C5a have been clearly demonstrated,
which is thought to underlie the profound leukopenia commonly
seen with cuprophane hemodialysis [9—111. These biologically
active glycopolypeptides possess anaphylactic properties in
vitro, that is, smooth muscle contraction, increased vascular
permeability, and release of histamine from mast cells [12—17].
It is therefore tempting to postulate that these anaphylatoxins
are responsible for some of the clinical adverse reactions seen
during hemodialysis. In support of this theory are recent
observations that clinical symptoms correlate with plasma C3a
antigen concentration in hemodialysis patients [8, 18].
Previous studies in sheep have shown that activation of blood
by cuprophane membrane led to drastic cardiopulmonary man-
ifestations including pulmonary hypertension and hypoxemia
[19, 21]. There are, however, conflicting reports on whether
induction of neutropenia abolishes these pulmonary changes
[19, 211. The nature of the mediator(s) is unclear, but has been
found to be heat—sensitive and inactivated by chelation with
ethylenediamine tetra-acetate. The present study was under-
taken to examine in a swine model the effects of contact with
cuprophane membrane on pulmonary and systemic hemody-
namics as well as arterial oxygenation. These experimental
results were compared with the effects observed with comple-
ment activation products in an attempt to substantiate the role
of these products in mediating the observed cardiopulmonary
and hematologic changes.
Methods
Animals
Normal four—breed cross male swine of 45 to 55 kg were
sedated with intramuscular ketamine hydrochloride and then
anesthetized with intravenous sodium pentobarbital. Five hun-
dred mliters of blood was collected by phlebotomy in a sterile
bag containing 500 U of sodium heparmn and the cells were
separated by centrifugation. The heparinized plasma was then
used to prepare cuprophane—activated plasma (CAP) or
zymosan—activated plasma (ZAP) as described below. The
animal was given 500 mliters of normal saline after the blood
collection and then allowed to recover from anesthesia. The
acute experiment was performed the next day.
Control plasma
Received for publication April 9, 1985,
and in revised form August 5, 1985
© 1986 by the International Society of Nephrology
Heparmnized autologous plasma which was incubated at 37°C
for 30 mm without other additives or stimulation served as
control.
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Cuprophane—activated plasma (CAP)
Curpophane hollow fiber hemodialyzers (CF-iS 11, Travenol
Laboratory, Inc. Deerfield, Illinois, USA) were rinsed with one
liter of sterile normal saline which was then flushed out with air.
One hundred and fifty mliters of heparinized autologous plasma
were recirculated from a sterile beaker through polyvinylchlo-
ride tubings (09-386 Cobe Laboratories, Inc., Lakewood, Col-
orado, USA) and the hemodialyzer at 37°C for 60 mm. The
plasma flow rate was 100 mliters per mm. The dialysate
compartment of the dialyzer was filled with normal saline and
clamped off. Cultures performed on these activated plasma
samples were negative for bacteria. Endotoxins were not de-
tectable by limulus lysate assay (Difco Laboratories, Detroit,
Michigan, USA).
Zymosan—activated plasma (ZAP)
Commercial baker's yeast (Fleischman) was boiled prior to
use. One gram of the boiled yeast cells was incubated with 50
mliter of heparinized autologous plasma at 37°C for 30 mm. The
mixture was then centrifuged at 10,000 x g for 20 mm and the
yeast pellet discarded.
Anaphylatoxin preparation
Fresh blood was collected from different swine without
anticoagulants, pooled and allowed to clot at room temperature.
The resulting porcine serum was then activated with zymosan
as described above. Complement fragment CSadesArg was par-
tially purified from the activated serum according to the method
of Gerard and Hugh J22]. Briefly, the activated serum was
precipitated with hydrochloric acid. The acid—soluble fraction
was neutralized with ammonium hydroxide and gel—filtered on a
BioRad P-60 column to remove larger proteins. The resulting
low molecular material was further purified by SP-Sephadex
ion—exchange chromatography. Protein was assayed using the
Lowry et al method with bovine serum albumin as standard
[23J.
Study protocol
Animals were studied according to four separate protocols: a)
i.v. bolus infusion of 0.7 mliter/kg BW of CAP (N =5); b) i.v.
bolus infusion of 0.7 mliter/kg BW of ZAP (N = 8); c) i.v. bolus
infusion of 20 to 50 tg of purified CSadeSAFg (N = 3); d) ex-vivo
recirculation of the animal's blood through a cuprophane hol-
low fiber dialyzer (CR1511) without dialysate passing through
(mock dialysis) (N = 4). The blood flow rate was 175 muter/mm.
Mock dialysis was preceded by recirculation through a bypass
circuit with polyvinylchloride tubings and no dialyzer. The
animal was given 2,000 U of sodium heparin before and 1,000 U
per hr during the extracorporeal circulation.
Acute experiments were performed the day after the plasma
was collected for CAP and ZAP preparation. The swine was
again sedated with 10 mg/kg ketamine hydrochloride, and then
anesthetized with 4 mg/kg sodium pentobarbital. It was then
intubated and placed on a volume respirator (Model #607,
Harvard Apparatus Co., Inc., Millis, Massachusetts, USA) set
to provide a tidal volume of 7 mliters/kg BW. Respiratory rate
was 12 to 15/mm. No supplemental oxygen was given. Normal
saline was given intravenously to replace the estimated fluid
loss during the whole experiment.
Femoral and carotid arteries were cannulated for systemic
blood pressure monitoring and blood sampling. Femoral and
jugular veins were cannulated for venous blood sampling. When
mock dialysis was performed, a femoral artery and vein were
used for blood access. A 7 french thermodilution Swan—Ganz
catheter (Instrumentation Laboratories, Lexington, Massachu-
setts, USA) was placed through the jugular vein into the
pulmonary artery. Cardiac output measurements were obtained
by thermodilution technique by injection of 10 mliters of
ice—cold saline into the proximal port of the Swan—Ganz cath-
eter. The curve was integrated using a Cardiac Output System
(Model #601, Instrumentation Laboratory, Lexington, Massa-
chusetts, USA). Systemic arterial, pulmonary arterial, and right
atrial pressure were recorded on an eight channel forced—ink
recorder (Model 2000, Gould Inc., Oxnard, California, USA).
Samples for blood gas measurements were collected in
heparinized syringes from a systemic arterial catheter and
placed immediately on ice. Systemic venous blood samples
were collected in tubes containing solid disodium ethylenedi-
amine tetracetate (Vacutainer, Becton—Dickinson, Rutherford,
New Jersey, USA).
Sample and statistical analysis
Systemic arterial partial pressure of oxygen (pO2), partial
pressure of carbon dioxide (pCO2) and pH were measured with
a blood gas analyzer (Radiometer BM-52, Coppenhagen, Den-
mark). Systemic venous white blood cell (WBC) counts were
measured with a cell counter (Model ZF, Coulter Electronics,
Hialeah, Florida, USA).
Systemic vascular resistance (SVR) in dyn.sec/cm5 was cal-
culated by (mean systemic arterial pressure — right atrial
pressure) mmHg x 80 -- cardiac output (liter/mm). Pulmonary
vascular resistance (PVR) in dyn.sec/cm5 was calculated as
(mean pulmonary arterial pressure — mean pulmonary wedge
pressure) mmHg x 80 cardiac output (liter/mm). Differences
in arterial blood pressure, cardiac output (CO), vascular resist-
ance, leukocyte count, partial pressure of oxygen and carbon
dioxide between time points were evaluated by Student's paired
t test. Values <0.05 were considered as statistically significant.
Values were reported as mean SEM.
Results
Infusion of 0.7 mliter/kg of control plasma intravenously did
not produce any significant hemodynamic alterations or
changes in leukocyte count, P°2 and pCO2.
Bolus infusion of 0.7 mliter/kg BW of CAP intravenously
induced fluctuation of mean systemic arterial pressure (SAP).
There was no consistent pattern of change. In some instances,
the pressure showed a modest rise as depicted in Figure 1(a). In
other instances, there was a slight and transient decrement
before a larger and longer increment in SAP as seen in Figure
1(b). When all animals were analyzed together, the mean SAP
increased from a baseline of 117.8 7.9 (mean 5EM) mmHg
to 169.2 7.4 mmHg at one to two mm after infusion (Fig. 2,
Table 1). Simultaneously, cardiac output decreased by 25%
whereas the total systemic peripheral resistance increased by
68%. Right atrial pressure (RAP) increased from 1.8 0.7
mmHg to 8.4 1.2 mmHg. Mean pulmonary pressure increased
2-1/2—fold from its baseline value. This was accompanied by a
tripling of the pulmonary vascular resistance. Peripheral white
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blood cell count dropped to 48.3%. Partial pressure of oxygen in
the systemic artery dropped by almost 30 mmHg. There was no
increase in the partial pressure of carbon dioxide.
Infusion of the same amount of zymosan—activated plasma
produced similar results. The mean SAP fluctuated as seen with
the infusion of cuprophane—activated plasma. Tracings of two
separate animals are shown in Figure 3. The animal in figure
3(b) demonstrated a more pronounced transient drop in SAP
than the animal in figure 3(a), but after ito 1.5 mm, a significant
increase was uniformly seen. Increase in mean PAP and RAP
were uniform, that is, all animals demonstrated a significant
increase without any initial decrease. Figure 4 and Table 1
summarize the results of all eight animals. The increase in mean
SAP, RAP, PAP, and PVR, as well as the decrease in peripheral
white blood cell (WBC) count and P°2 were of the same order
of magnitude as those seen with cuprophane—activated plasma.
pCO2
Time, minutes
Fig. 2. Responses of swine (N = 6) to i.v. infusion of CAP. "P < 0.01
vs. baseline.
The changes in cardiac output and total systemic vascular
resistance were not statistically significant.
The responses to intravenous bolus infusion of 20 to 50 j.g of
purified porcine CSjes&jg are shown in Figure 5 and Table 1. A
representative tracing is shown in Figure 6. Mean SAP increased,
but did not reach statistical significance (0.05 <P < 0.1). There
were, however, prominent rises in RAP, mean PAP and pulmo-
nary vascular resistance. Cardiac output decreased from 4.5 0.6
liter/mm to 3.2 0.6 liter/mm (P < 0.05). Peripheral WBC counts
decreased to 41.0 13.3% of baseline (P < 0.05). The decrease in
P°2 did not reach statistical significance.
No significant pulmonary hypertension or hypoxemia was
seen with extracorporeal circulation through the bypass circuit.
Responses to mock dialysis through a cuprophane membrane
are presented in Table 1. Mean PAP rose from 28.5 1.7
mmHg to 38.3 1.9 mmHg at s mm (P < 0.05), and continued
to be elevated at 10 mm (36.0 2.7 mmHg, P < 0.05).
However, peripheral WBC counts did not decrease significantly
until 10 mm after the onset of the recirculation. This temporal
dissociation between pulmonary hypertension and peripheral
leukopenia is clearly shown in a representative animal (Fig. 7).
Discussion
Leukopenia occurs almost universally in patients undergoing
hemodialysis with cuprophane membranes [10, 11, 24—271. We
have previously demonstrated that complement activation with
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Fig. 1. Hemodynamic responses to i.v. bolus infusion of 0.7 mliter/kg
BW of CAP. Abbreviation LVP is left ventricular pressure. See Table 1
for other abbreviations.
I —-
0 15
Baseline 1 Mm 15 Mm Baseline S Mm 10 Mm
Mean SAP (mmHg) 126.7 7.3 189.3 10.9 125.0 7.6 123.3 11.8 121.8 6.4 118 9.7
CO (liter/mm) 4.5 0.6 3,2 0.6a 4.7 0.7 4.6 0.6 4.7 0.2 4.6 0.4
SVR (dyn.sec/cm5) 2318 414 4872 + 1050 2224 454 2176 348 2080 86 2016 176
RAP (mmflg) 2.7 0.9 15.0 l,2 3.0 10.7 0.7 0.3 2.7 1.4 1.7 1.2
Mean PAP (mmHg) 28.7 6.4 68.3 6,Oa 26.3 4.3 28.5 1.7 38,3 1.9 36.0 2.7
PYR (dyn.sec/crn5) 546 162 1856 399 461 131 — —
WBC (%) 100 41.0 ÷ 13.Y 85.7 14.9 100 83.3 8.8 49.8 3,7'
P02 (mmHg) 67.7 + 9.3 59.3 9.6 62.7 6.9 75.7 15.8 59.7 8.0 78.7 18.2
pCO2 (mmHg) 43.7 0 43.7 0 43.3 6.5 44.7 3.8 49,0 4,3a 45,3 4.4
a p c 0.05, and
F < 0.01 vs. baseline. All values are reported as mean 5CM.
Abbreviations are: SAP, systemic arterial pressure; CO, cardiac output; SVR, systemic vascular resistance; RAP, right atrial pressure; PAP,
pulmonary arterial pressure; PVR, pulmonary vascular resistance; WBC, peripheral venous white blood cell count; P°2 and pCO2 are partial
pressure of oxygen and carbon dioxide in the systemic arterial blood.
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Fig. 3. Heniodynamic responses to iv, bolus infusion of 0.7 muter/kg
BW of ZAP. A and B are tracings in two separate animals, demonstrat-
ing the fluctuations in SAP. The responses in PAP and RAP were
uniform; all showing significant increases without an initial decrease.
formation of C3a and C5a antigens also occurs during such
procedures [10, 11]. We and other investigators have further
shown that injection of cuprophane—activated plasma into ex-
perimental animals produces leukopenia, pulmonary hyperten-
sion and hypoxemia [19—21, 28, 29]. Since C3a and CSa are
anaphylatoxins capable of contracting smooth muscles in vitro
Ui, 14, 22, 301 and CSa also possesses chemotactic properties
[161, it is reasonable to postulate that they are the mediators of
the responses to cuprophane—activated plasma. In further sup-
port of this hypothesis, the present study identifies that the
response produced by intravenous infusion of cuprophane—ex-
posed plasma is very similar to that produced by activated
complement components.
More specifically, intravenous infusion of cuprophane—acti-
vated plasma produced drastic increases in pulmonary arterial
pressure and pulmonary vascular resistance. Although the
patterns of systemic blood pressure response were not uniform,
there was a general increase which persisted over several mm.
In some instances there was a very transient mild decrease in
systemic blood pressure prior to the more prominent increase.
The mechanism of this transient decrease in this complex
system may not be specifically identified, but it can be postu-
lated that the immediate intense pulmonary vascular constric-
tion impeded the right—sided cardiac output. This was followed
later by intense constriction of the systemic vasculature, which
led to systemic hypertension in spite of a persistently dimin-
ished cardiac output. Elevation of left ventricular end—diastolic
pressure had also been observed prior to the onset of systemic
hypertension. These hemodynamic changes were accompanied
by marked peripheral leukopenia and arterial hypoxemia. How-
ever, a cause and effect relationship between these phenomena
and the hemodynamic changes cannot be directly inferred.
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Table 1. Responses to i,v. bolus infusion of cuprophane—activated plasma, zymosan—activated plasma, and purified CSaacaArg at baseline, one,
and 15 mm after infusion.
CAP (N — 6)
Baseline 1 Mm 15 Mm Baseline 1 Mm
ZAP (N = 8)
15 Mm
Mean SAP (mmHg) 117.8 7.9 169.2 ÷ 74b 113 7.6 127.9 4.6 168.1 9.8k 125.3 4.7
CO (liter/mm) 4,4 0.3 3.3 0.3k 4.1 0.4 4.9 0.3 4.3 0.4 4.9 0.3
SVR (dyn.sec/cm5) 2128 + 104 3584 480' 2264 24 2072 184 2296 240 2064 112
RAP (mmHg) 1.8 0.7 8.4 1,2b 2.3 0.7 3.5 0.8 16.1 13b 3.9 0.8
Mean PAP (mmHg) 24.0 3.5 59.1 + 445 26.5 4.6 21.6 0.9 63.9 3,3i 26 1,6b
PVR(dyn.sec/cm) 332 42 1110 l22i 336 72 280 40 960 64 460 ÷ 60
WBC (%) 100 48.3 3,45 98.3 5.8 100 28.9 2.2k 97.0 9.5
PO2 (mmHg) 86.8 11.8 57.2 9,55 74.6 10.3 90.9 4.8 65.0 4,05 81.8 4.Y'
pCO2 (mmflg) 42.0 2.7 47.0 4.8 42.0 2.0 34.9 ÷ 1.8 35.3 2.9 34.4 2.1
CSadcaxrg (N = 3) HD (N = 4)
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Fig. 4. Responses of swine (N = 8)10 i.V. infusion of ZAP. P < 0.01
vs. baseline.
In comparison, zymosan—activated plasma elicited very sim-
ilar responses. Systemic arterial pressure, right atrial pressure,
pulmonary arterial pressure and pulmonary vascular resistance
all increased, whereas arterial oxygenation and peripheral
leukocyte counts decreased. Significant alterations in cardiac
output and systemic vascular resistance were however, not
observed.
Zymosan activates the alternative pathway of complement,
resulting in the formation of C3a and C5a. Both of these
anaphylatoxins are capable of contracting guinea pig ileum in
vitro. To substantiate that CSa or its desArg derivitive is
responsible for the observed responses to cuprophane—activat-
ed or zymosan—activated plasma, the animals were challenged
with CSadesArg. Infusion of purified porcine CSadesArg also
showed a pattern of response very similar to that elicited by
activated plasma. Right atrial pressure, pulmonary arterial
pressure and pulmonary vascular resistance increased. There
were a marked peripheral leukopenia and drop in cardiac
output. Changes in systemic blood pressure, systemic vascular
resistance and arterial oxygenation were consistent in direction
with those induced by activated plasma but were not statisti-
If—4Po2
cally significant, probably because of the scatter and relatively
small number of data points.
The in vivo hypertensive and leukopenic responses to por-
cine C5adesArg in the present study agrees with the in vitro
effects reported in the literature. Porcine CSadesArg has been
reported to be chemotactic [31]. It also contracts guinea pig ileal
smooth muscle at nanomolar concentration, a potency compa-
rable to that of its parent compound, C5a [321.
Craddock et al found increase in pulmonary artery pressure
and mediastinal lymph flow, leukopenia as well as hypoxemia
when cuprophane—incubated plasma was injected into sheep
[19]. Leukopenia and hypoxemia were also seen in rabbits upon
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Fig. 6. Representative traciAg of mean SAP and mean PAP in swine in
response to i.v. infusion of purified C5adA,.5
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such challenge. Walker et al, subsequently employed a modified
model in which whole blood from the sheep was allowed to stay
in static contact with a cuprophane dialyzer ex vivo [20]. When
this cuprophane—activated blood was reinjected into the animal,
pulmonary hypertension, hypoxemia, leukopenia, decrease in
cardiac output and cardiac arrhythmia were observed. In addi-
tion to responses observed by previous investigators, we also
noted systemic hemodynamic changes in the swine in the
present study.
Craddock et al originally postulated that the physical plugging
of the pulmonary vessels induced the pulmonary hypertension
and hypoxemia. This hypothesis was supported by his obser-
vation that prior induction of leukopenia abolished the hypox-
emia in rabbits and sheep [191. The pulmonary hypertension in
the sheep was also inhibited. In contrast, Walker et al found
that pulmonary hypertension and hypoxemia persisted when
leukopenic sheep were challenged with cuprophane—activated
blood, suggesting that the leukocytes are not necessary to
induce the pulmonary changes [21].
The temporal dissociation of the pulmonary hypertension
from the leukopenia in the mock dialysis of the present study
strongly suggests that cuprophane—induced pulmonary hyper-
tension is not the consequence of pulmonary leukosequestra-
tion and that vasoactive humoral factors are probably respon-
sible. One likely candidate for these humoral factors is CSadCSArg
since infusion of this complement fragment reproduced the
pulmonary hypertension. This does not, however, exclude the
participation of other humoral substances such as arachidonic
teers was associated with a decrease in arterial oxygen tension
[39]. The present study suggests that CSadesArg is a mediator of
this hypoxemia, although the exact pathophysiology is un-
known. Increase in pulmonary artery pressure and pulmonary
vascular resistance are drastic in the animal model. These
changes have also been observed in patients undergoing
hemodialysis, occasionally accompanied by right ventricular
decompensation [40, 41]. Dyspnea and non-anginal chest pains
are common but often difficult to assess. Potentially they are
related to the hypoxemia and pulmonary hypertension.
Patients with the so—called "first—use syndrome" with
cuprophane dialysis have manifestations not dissimilar to those
seen in our animals. In particular, systemic hypertension occa-
sionally occurs [2, 5]. Although the pathogenesis of this "syn-
drome" is probably multifactorial, we speculate that the ana-
phylatoxins are causative in some of the patients who have
higher end organ sensitivities, slower catabolism of the active
molecules or higher propensity to generate these complement
fragments. The latter is supported by the observation by Hakim
et al that patients who suffered from the first—use syndrome are
associated with higher plasma C3adeSArg concentration than
those who did not [81.
It should be pointed out that bolus infusion of cuprophane—
activated plasma in the animal studies might not be completely
comparable to the effects of the cuprophane membrane in
clinical hemodialysis. Mock dialysis provides a better analogy.
However, bolus infusion produces more drastic responses and
provides a more sensitive model to study the effects of
blood—membrane interaction and its mediators.
In summary, the present study demonstrated that both sys-
temic and pulmonary hemodynamic changes occur with intra-
venous infusion of cuprophane—activated plasma in experimen-
tal swine. This is accompanied by peripheral leukopenia and
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120 acid metabolites, which may be the final mediators of the
vasoconstrictive action of complement activation products [33].
Available data indicate that products of the cyclooxygenase
pathway are responsible [21, 34]. It should be noted that the
present study does not indicate whether the leukocytes are
necessary to produce the pulmonary hypertension. Although80 physical plugging is not the etiology, the leukocytes can poten-
tially participate by liberating vasoactive substances.
In agreement with previous investigation [20], our study
showed that extracorporeal circulation through the bypass
circuit without a dialyzer did not elicit any significant alteration.
This indicates that the hypoxemia and hemodynamic changes
are induced by the cuprophane membrane.
Adverse reactions during cuprophane hemodialysis are often
reminiscent of the response induced by cuprophane—activated
plasma in animals. Most investigators agree that the leukopenia
___________________________________
is caused by the leukocyte—aggregating effect of C5a and its
desArg derivative [9, 10]. Hypoxemia is also seen very fre-
quently. Although acetate dialysate is undoubtedly a major
factor in the pathogenesis of hypoxemia [35, 36], blood—mem-
brane interaction is also a likely contributor to this disorder.
Studies by Hakim and Lowry [37] and DeBacker et al [38]
clearly point out the more favorable oxygenation when patients
115 20 are dialyzed with membranes which activate less complement,
regardless of whether acetate or bicarbonate dialysate is used.
Time, minutes Indeed, preliminary data from BergstrOm et al demonstrated
Dialyzer that mock dialysis with cuprophane on normal human volun-
Fig. 7. Mean SAP, PAP, peripheral WBC counts and systemic arterial
P°2 in a swine in response to extracorporeal recirculation through a
cuprophane membrane. Marked pulmonary hypertension preceded
peripheral leukopenia.
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arterial hypoxemia. Zymosan—activated plasma produced sim-
ilar results, suggesting that products of alternative complement
pathway may mediate these changes. The similarity to re-
sponses to CSadesMg further suggests that activation products
from C5 are responsible. The temporal dissociation of pulmo-
nary hypertension from peripheral leukopenia suggests that
other vasoactive substances, but not leukosequestration per se,
cause the hemodynamic changes observed during extracorpo-
real circulation through the cuprophane membrane.
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